GleamWall
中文EN

LKFT Lakefront Biotherapeutics NV IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1421876 · Reporting currency EUR

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY303.5%
TTM net income YoY333.1%
TTM EPS YoY334.8%
Revenue 3-yr CAGR66.4%
Net income 3-yr CAGR—

Margins

Gross margin97.3%
Operating margin26.5%
Net margin28.9%
FCF margin-24.4%
EBITDA margin—

Returns

ROE10.5%
ROA8.5%
ROIC (approx.)9.9%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets5.0%
Debt / equity0.00x
Current ratio20.15x
Interest coverage285.34x

Cash quality & payout

Operating cash flow / net income-0.80x
Accruals ratio15.3%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2021Q22021-06-302020Q22020-06-302019Q22019-06-302018Q22018-06-302017Q22017-06-30
Income statement
Revenue139.77M99.59M58.74M49.68M26.93M
R&D expense138.87M147.45M94.37M81.68M47.98M
SG&A expense46.44M37.28M13.71M8.50M6.33M
Operating income-46.75M-88.17M-44.37M-33.75M-21.68M
Pretax income-64.96M-116.61M-47.19M-21.70M-35.55M
Income tax-630,000373,00061,00075,00092,000
Net income-64.33M-115.04M-47.25M-21.77M-35.64M
EPS (basic)-0.98-1.77-0.86-0.42-0.71
EPS (diluted)-0.98-1.77-0.86-0.42-0.71
Balance sheet
Cash & equivalents2.64B2.38B1.15B1.07B1.26B
Short-term investments2.36B3.18B———
Receivables88.13M31.35M42.07M19.11M—
Inventory———267,000—
Current assets5.13B5.62B1.21B1.11B—
PP&E, netmay include right-of-use assets (IFRS)111.90M73.79M51.18M17.85M—
Intangibles63.07M39.25M7.19M1.40M—
Total assets5.43B5.85B1.36B1.20B—
Current liabilities576.99M618.54M188.71M246.59M—
Total liabilities2.77B3.08B214.48M318.69M—
Shareholders' equity2.66B2.77B1.14B885.66M1.07B
Cash flow statement
Operating cash flow—————

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.